FDA's Outlook on the Drug Approval Drought
This article was originally published in RPM Report
Executive Summary
You would have to go back a quarter century to find a year with as few new drug approvals as 2007. There may be no one more concerned with the sinking approval rate of new molecular entities than FDA's Office of New Drugs Director John Jenkins. The RPM Report asked Jenkins why the stream of NMEs coming on to the market has slowed to a trickle.
You may also be interested in...
Treat and Trade: The New Priority Review Voucher Market
Starting in September, pharmaceutical companies will have the opportunity to buy the right to a faster FDA review on the open market. If it works, the priority review voucher program could revolutionize development of drugs for neglected diseases, while increasing the value of more traditional commercial products in the US.
Treat and Trade: The New Priority Review Voucher Market
This is a reprint of the feature of the same title appearing in the July 2008 issue of The RPM Report.
Treat and Trade: The New Priority Review Voucher Market
Starting in September, pharmaceutical companies will have the opportunity to buy the right to a faster FDA review on the open market. If it works, the priority review voucher program could revolutionize development of drugs for neglected diseases, while increasing the value of more traditional commercial products in the US.